

**Listing of Claims**

- 1-7. (canceled)
8. (currently amended) A method of preserving a kidney for transplantation which comprises contacting the kidney, in the presence of a growth factor, with an amount of a gp130 receptor ligand effective to preserve the kidney wherein the gp130 receptor ligand is chosen from the group consisting of a leukemia inhibitory factor, a cardiotrophin, a ciliary neuronotrophic factor, an interleukin-6, a polypeptide comprising consecutive amino acids having a sequence identical to the sequence of a naturally occurring human leukemia inhibitory factor, and a polypeptide comprising consecutive amino acids having a sequence identical to the sequence of a naturally occurring human growth factor.
9. (original) The method of claim 8, wherein the gp130 receptor ligand is a leukemia inhibitory factor.
10. (previously presented) The method of claim 8, wherein the effective amount of the gp130 receptor ligand is an amount from about 5ng/ml to about 200 ng/ml.
11. (canceled)
12. (canceled)
13. (currently amended) The method of claim 8, wherein the growth factor is selected from the group consisting of one or more of a TGF $\alpha$ , a FGF-2, a FGF-9, a TIMP-1, or a TIMP-2.

14. (currently amended) The method of claim 8, wherein the growth factor is selected from the group consisting of TGF $\alpha$ , a FGF-2, or FGF-9 and the effective amount of TGF $\alpha$ , a FGF-2, or FGF-9 is an amount from about 1 ng/ml to about 100 ng/ml.
15. (canceled)
16. (previously presented) The method of claim 8, wherein the growth factor is TIMP-1 or TIMP-2 and the effective amount of TIMP-1 or TIMP-2 is an amount from about 200 ng/ml to about 2  $\mu$ g/ml.
- 17-21. (canceled)